QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.108.048645v1 74/4/1152    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Uchaipichat, V. Articles by Miners, J. O. Search for Related Content PubMed PubMed Citation Articles by Uchaipichat, V. Articles by Miners, J. O.

Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites

Department of Clinical Pharmacology, Flinders University, Adelaide, Australia (V.U., P.I.M., J.O.M.); School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom (A.G., J.B.H.); and Molecular Medicine, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California (J.A.W.).

Interactions between the UGT2B7-catalyzed glucuronidation of zidovudine (AZT), 4-methylumbelliferone (4MU), and 1-naphthol (1NP) were analyzed using multisite and empirical kinetic models to explore the existence of multiple substrate and effector binding sites within this important drug metabolizing enzyme. 4MU and 1NP glucuronidation by UGT2B7 exhibit sigmoidal kinetics characteristic of homotropic cooperativity (autoactivation), which may be modeled assuming the existence of two equivalent, interacting substrate binding sites. In contrast, UGT2B7-catalyzed AZT glucuronidation follows hyperbolic (Michaelis-Menten) kinetics. Although 4MU and 1NP decreased the binding affinity of AZT, the kinetics of AZT glucuronidation changed from hyperbolic to sigmoidal in the presence of both modifiers. Data were well described by a generic two-substrate binding site model in which there is no interaction between the sites in the absence of 4MU or 1NP, but heterotropic cooperativity results from the binding of modifier. Inhibition of 4MU and 1NP glucuronidation by AZT and interactions between 4MU and 1NP required more complex three-site models, where the modifier acts via a distinct effector site to alter either substrate binding affinity or V_max without affecting the homotropic cooperativity characteristic of 4MU and 1NP glucuronidation. It is noteworthy that 1NP inhibited 4MU glucuronidation, whereas 4MU activated 1NP glucuronidation. The results are consistent with the existence of two "catalytic" sites for each substrate within the UGT2B7 active site, along with multiple effector sites. The multiplicity of binding and effector sites results in complex kinetic interactions between UGT2B7 substrates, which potentially complicates inhibition screening studies.

Received for publication May 5, 2008.

Accepted for publication July 21, 2008.

Address correspondence to: Professor John Miners, Department of Clinical Pharmacology, Flinders University School of Medicine, Flinders Medical Centre, Bedford Park, SA 5042. Australia, E-mail: john.miners{at}flinders.edu.au

This article has been cited by other articles:

				A. E. Schwaninger, M. R. Meyer, J. Zapp, and H. H. Maurer The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxymethamphetamine (Ecstasy) Phase II Metabolites R- and S-3-Methoxymethamphetamine 4-O-Glucuronides Drug Metab. Dispos., November 1, 2009; 37(11): 2212 - 2220. [Abstract] [Full Text] [PDF]

				K. C. Olson, R. W. Dellinger, Q. Zhong, D. Sun, S. Amin, T. E. Spratt, and P. Lazarus Functional Characterization of Low-Prevalence Missense Polymorphisms in the UDP-Glucuronosyltransferase 1A9 Gene Drug Metab. Dispos., October 1, 2009; 37(10): 1999 - 2007. [Abstract] [Full Text] [PDF]

				A.-S. Belanger, P. Caron, M. Harvey, P. A. Zimmerman, R. K. Mehlotra, and C. Guillemette Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine Drug Metab. Dispos., September 1, 2009; 37(9): 1793 - 1796. [Abstract] [Full Text] [PDF]